Skip to content

Erasca, Inc. ERAS Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$2.67B+126%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$445.22M-84.9%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.59M+7.4%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$103.61M-38.3%
Exelixis logo
ExelixisEXEL
$251.34M+34.5%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$17.83M+870%

Other financials

Income statement

See full
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s operating income?
Erasca, Inc. (ERAS) reported operating income of -$187.91M in Q1 2026.
How has Erasca, Inc.'s operating income changed year-over-year?
Erasca, Inc.'s operating income decreased by 427.4% year-over-year, from -$35.63M to -$187.91M.
What is the long-term trend for Erasca, Inc.'s operating income?
Over 4 years (2021 to 2025), Erasca, Inc.'s operating income has grown at a 3.1% compound annual growth rate (CAGR), from -$124.88M to -$140.91M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.